Skip to main content

Crohn's Disease clinical trials at UCLA

3 in progress, 2 open to eligible people

Showing trials for
  • Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

    Los Angeles, California and other locations

  • Dietary Composition in Crohn's Disease

    open to eligible people ages 18-75

    Patients with inflammatory bowel disease (IBD) often have narrowed microbial diversity and altered composition and function of the gut microbiome. We anticipate the anti-inflammatory diet, when compared with the usual diet, to produce favorable changes in these multi-omics profiles. These findings will provide insight into the interactions between diet and host biology, while providing clues on the mechanisms of diet therapy's effect and CD pathogenesis.

    Los Angeles, California

  • CDPATH™ to Help Manage and Treat Crohn's Disease

    Sorry, in progress, not accepting new patients

    CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

    Orange, California and other locations

Our lead scientists for Crohn's Disease research studies include .

Last updated: